back to overview

news

MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

August 10, 2021 + Jessica Di Palo
3 Min read

Investment led by MTIP enables the company to reduce the risk of clinical research, improve R&D productivity, and accelerate scientific breakthroughs through artificial intelligence (AI) and natural language processing (NLP).

MTIP invests in intelligencia

MTIP is delighted to announce MTIP Fund II’s fourth investment in Intelligencia, whose AI-driven software platform enables pharmaceutical and biotechnology companies to revolutionize the drug development process and reduce risk. The closure of an oversubscribed $12M investment round was led by MTIP. Other investors include Big Pi Ventures, Synetro Group, as well as several of the company’s existing investors. ZS, a global professional services firm, has also participated in this round.

The company’s founders, Dimitrios Skaltsas and Vangelis Vergetis, met while at McKinsey & Company, and have spent more than a decade in the intersection of clinical development, data science, and technology solutions. Forbes recently included Intelligencia in their list of “America’s top 50 most promising AI companies”.

Intelligencia is an AI-driven technology company that focuses on minimizing the risk of drug development and enabling external innovation. It currently works with top-10 and mid-size global biopharmaceutical companies, smaller biotechs, prominent research centers, as well as investors in the biopharmaceutical space. With a focus on increasing R&D productivity, the company offers a suite of decision-making support solutions that enable its customers to minimize the risk of drug development, as well as streamline productivity and lower cost. Its platform allows customers to:

  • Accurately and efficiently assess the probability of success of pipeline drugs, with supporting rationale;
  • Unlock the optimal trial design, with comprehensive benchmarks linked to clinical trial success;
  • Identify and prioritize additional potential indications to explore for each asset;
  • Guide business development decisions by quickly and objectively comparing the attractiveness of external assets, based on a variety of features, including the underlying biology, clinical and regulatory data, and company characteristics; and
  • Identify emerging technologies and scientific breakthroughs to gain competitive insights and enable identification of “the next big thing” early.

The company currently employs more than 40 people across the company’s headquarters in New York and the R&D center in Athens, Greece. The proceeds from this round will expand its R&D team in Athens, grow its sales and customer success teams in the US and in Europe, as well as allow it to work even more closely with customers and partners as they seek to incorporate their private/proprietary data into the company’s models.

“As we continue to aggressively expand Intelligencia’s business, we are privileged to have the support and guidance of industry veterans and company builders alike”, says Vangelis Vergetis. “Our aim has always been to make a difference when it comes to the incredibly risky business of drug development, and this funding round will allow us to continue to expand our product offering, our proprietary data, and our customer base.”

Danchen Zhao, who joins the Board of Directors on behalf of MTIP, said: “We see Intelligencia as an innovation leader in ML-based predictive analytics, offering actionable insights to life science organizations. We are impressed by their complementary team of data scientists, biologists and software engineers, that together continuously improve and expand their platform.” Dr. Christoph Kausch continued: “At MTIP, we see great potential in Artificial Intelligence and Machine Learning in the Life Science vertical. Intelligencia’s platform enables faster and more efficient drug development and helps to improve the success rate of novel therapies. This investment aligns with our philosophy of supporting innovation that enhances patients’ quality of life and life expectations across therapeutic areas.”

“Increasingly, innovation in science and R&D requires technical expertise,” said Pratap Khedkar, CEO of ZS. “We are committed to supporting and partnering with innovative companies like Intelligencia to drive the adoption of next-generation technical capabilities – and robust data-driven decision making – for the biopharmaceutical industry.”

Dimitrios Skaltsas, talking about the team behind building a software product that is centered around specific customer needs, says: “Our fuel has been our unique knowledge graph, built on expertly curated data and ontologies. Equally, what has been crucial and much rewarding in our journey is bringing together a high-octane interdisciplinary team with both hard and soft skills, as well as constantly evolving with the direct input from our users at major organizations and cutting-edge biotech companies.”

 

For more information please contact:

Jessica Di Palo
Head of Marketing and Communications at MTIP
Phone: +41 61 551 12 50
E-mail: communications@mtip.ch

 

About Intelligencia

Intelligencia is an AI-driven technology company that focuses on minimizing the risk of drug development and enabling external innovation. It transforms how R&D and Business Development executives think about and assess the risk of clinical development programs and enables them to make more informed and data-driven decisions as they evaluate their own pipelines and/or external opportunities. Visit our website www.intelligencia.ai.

About MTIP

MTIP is a healthtech growth capital investor based in Basel, Switzerland. It invests in digital health and digitally-connected medical device companies, with offerings that provide clear health-related economic benefits. Its entrepreneurial investment team, which has complementary private equity skills and exceptional deal-making capabilities, actively works with portfolio companies to boost growth. MTIP efficiently deploys capital to unlock value and generate attractive returns for our investors. Visit www.mtip.ch to learn more.

About ZS

ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 10,000-plus ZSers in 28 offices worldwide, we are passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com.

 

Share the Article

blog

SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right

news

MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round

news

MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia

blog

Private Equity 101: Part one – Glossary

Are you new to the healthtech space?

blog

Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey

blog

Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations

news

MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II

blog

How to pitch to a healthtech Investor

Blog Pitching

news

MTIP invests in Koa Health to make mental health treatment more accessible

New investment in Koa Health

news

MTIP scored fantastic grades in the UNPRI assessment report of 2020

UNPRI Report grades 2020

press

4 Health VCs Share Their Business Priorities and What is Next

Interview Techtour

news

MTIP invests in Trialbee

New investment in Trialbee

news

TytoCare closes $50 million round as the demand for telehealth accelerates

TytoCare closes new round

news

The digital healthtech sector is expanding – and so are we!

Two new empolyees start in April

news

MTIP has sucessfully exited Blueprint Genetics

Blueprint exit January 2020

news

New MTIP investment in Oviva

New investment in Oviva

press

Whitepaper: A positive prognosis for the future of healthtech

Our first Whitepaper

press

Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch

Elite Summit 2019

news

MTIP Healthcare Clinic 2019

Healthcare clinic 2019

New MTIP investment in Cynerio

New investment in Cynerio

news

MTIP invests in Lumeon Ltd.

New investment in Lumeon

Magenverkleinerung mit der Handnähmaschine

Nitinotes news paper article

news

New MTIP investment in Quanta Dialysis Technologies

New investment in Quanta